GOUT AND NONALCOHOLIC FATTY LIVER DISEASE: EFFECT OF ENTEROSORPTION’S ADDITION TO COMMON TREATMENT
DOI:
https://doi.org/10.11603/ijmmr.2413-6077.2019.2.10886Keywords:
gout, nonalcoholic fatty liver disease, enterosorbent, treatmentAbstract
Background. Gout is still one of the major health problems despite significant advances in treatment in recent years. It has been proved that pathogenetic mechanisms of development and progression of gout are associated with nonalcoholic fatty liver disease. Complex pathogenic treatment of patients aimed at different parts of the pathological process has recently been supplemented with the enterosorbents.
Objective. The aim of the research is to study the clinical features of gout with concomitant nonalcoholic fatty liver disease (NAFLD) and to evaluate the effect of carbon enterosorbent on its course.
Methods. 123 patients were involved in the study. They were divided into 2 groups: group 1 included patients with gout without liver damage, and group 2 included patients with concomitant NAFLD. Each of these groups was divided into subgroups, in which the patients received carbon enterosorbent carboline plus basic treatment. The control group consisted of 30 healthy persons. Anamnesis, physical examination, uric acid (UA), C-reactive protein (CRP) content, erythrocyte sedimentation rate (ESR) in serum were determined. Gout activity was evaluated using the Gout Activity Score (GAS).
Results. Basic treatment in combination with carbon enterosorbent contributed to faster cure of intoxication, pain and joint syndromes, as well as decrease of the inflammatory process activity.
Conclusions. The course of gout in the patients with concomitant NAFLD is more severe. Adding of carbon granular enterosorbent carboline in the complex treatment of patients with gout with or without concomitant NAFLD in the exacerbation phase contributes to a faster cureing dynamics of clinical and laboratory manifestations of the disease.
References
Herasymenko SI, Poluliakh MV, Duda MS, Pshenychnyi TIe. Current aspects of conservative treatment of acute gouty arthritis. Chronicle of traumatology and orthopedics. 2013;1-2:204-7.
Orlova IV. Influence of disease activity on quality of life of patients with gout. Ukrainian Journal of Medicine, Biology and Sport. 2018;3(5):127–31.
doi: 10.26693/jmbs03.05.127
Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence. 2017;11:795–800.
doi:10.2147/PPA.S97927
Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10-5.
doi: 10.3111/13696998.2010.540874
Svintsitskyi AS. Current views on the diagnosis and treatment of gout. Health of Ukraine. Rheumatolog. 2013 February: 70-2.
Barskova VG, Eliseev MS, Denisov IS, Eliseeva ME, Belikov OA, Fadienko GR, i dr. The frequency of metabolic syndrome and concomitant diseases in patients with gout. Data from a multicenter study. Scientific and Practical Rheumatology. 2012;6(50):15-8.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017; 15(1): 123.
doi:10.1186/s12916-017-0890-9
Skliarov YeYa., Aksentiichuk KhB., Kurliak NV. Monitoring of liver function disorders in patients with non-alcoholic fatty liver disease on the background of metabolic syndrome. Hepatology. 2015;1: 34-41.
Tkachuk SO, Bashta HV, Lapovets LIe, Zaletskyi MP. Changes in carbohydrate and lipid metabolism and C-reactive protein in patients with coronary heart disease and fatty hepatosis. Medical and Clinical Chemistry. 2016;18(4):29-33.
doi: 10.11603/mcch.2410-681X.2016.v0.i4.7252
Kondratiuk VIe, Tarasenko OM. Hyperuricemia and gout: the current state of the problem. Ukrainian Rheumatology Journal. 2016;3:30–7.
Scirè C, Carrara G, Viroli C, Cimmino M, Taylor W, Manara M, et al. Development and First Validation of a Disease Activity Score for Gout. Arthritis Care & Research. 2016; 68 (10): 1530-7.
doi: 10.1002/acr.22844
Abrahamovych OO, Faiura OP, Abrahamovych UO. Comorbidity: a modern perspective on the problem; classification (message second). Lviv Clinical Bulletin. 2016;1:31-9.
Svintsitskyy AS, Kozak NP, Ostafiichuk AS. Pecularities of gouts’ course in association with the metabolic syndrome. Ukrainian Rheumatology Journal. 2011;4:46.
Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J. Hepatol. 2019;70(3):531-44.
doi: 10.1016/j.jhep.2018.10.033
Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis. 2010;68(3):199-203.
Orlovsky VF, Murenets NO. Chronic inflammation in nonalcoholic fatty liver disease. Pathologia. 2010;7(3):99-102.
Svіntsіtskiy AS. Diagnosis and treatment of rheumatic diseases: manual. Kiev: The Publishing House of the Medknyga; 2017. 372 р.
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
